Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2000

01-12-2000 | Review

Molecular biology of breast cancer metastasis ‘Has it spread?’: Disarming one of the most terrifying questions

Author: Patricia S Steeg

Published in: Breast Cancer Research | Issue 6/2000

Login to get access

Excerpt

There is good news to report. I list below a number of significant advances in breast cancer metastasis research. Each of these shifts has the potential to influence translational research (ie drug development, preclinical studies and clinical trials). I offer my thanks to the authors who contributed the accompanying reviews. …
Literature
1.
Chambers AF, Naumov GN, Vantyghem SA, Tuck AB: Molecular biology of breast cancer metastasis: clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2000
2.
Al-Mehdi A, Tozawa K, Fisher A, Shientag L, Lee A, Muschel R: Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med. 2000, 6: 100-102. 10.1038/71429.CrossRefPubMed
3.
Welch DR, Steeg PS, Rinker-Schaeffer CW: Molecular biology of breast cancer metastasis: genetic regulation of human breast carcinoma metastasis. Breast Cancer Res. 2000
4.
Yoshida B, Dubauskas Z, Chekmareva M, Christiano T, Stadler W, Rinker-Schaeffer C: Mitogen-activated protein kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 1999, 59: 5483-5487.PubMed
5.
Leone A, Flatow U, VanHoutte K, Steeg PS: Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization, and enzymatic activity. Oncogene. 1993, 8: 2325-2333.PubMed
6.
Yoneda T, Michigami T, Yi B, Williams P, Niewolna M, Hiraga T: Use of bisphosphonates for the treatment of bone metastases in experimental animal models. Cancer Treatment Rev. 1999, 25: 293-299. 10.1053/ctrv.1999.0133.CrossRef
7.
Yin J, Selanger K, Chirgwin J, Dallas M, Grubbs B, Wieser R, Massague J, Mundy G, Guise T: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999, 103: 197-206.CrossRefPubMedPubMedCentral
8.
Price J: Metastasis from human breast cancer cell lines. Breast Cancer Res Treat. 1996, 39: 93-102.CrossRefPubMed
9.
Rye P, Norum L, Olsen D, Vik SG, Kaul S, Fodstad O: Brain metastasis model in athymic nude mice using a novel MUC1-secreting human breast cancer cell line, MA11. Int J Cancer. 1996, 68: 682-687. 10.1002/(SICI)1097-0215(19961127)68:5<682::AID-IJC20>3.3.CO;2-5.CrossRefPubMed
10.
Hoffman R: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 1999, 17: 343-359. 10.1023/A:1006326203858.CrossRefPubMed
11.
Maniotis A, Folberg R, Hess A, Seftor E, Gardner L, Pe'er J, Trent J, Meltzer P, Hendrix M: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol . 1999, 155: 739-752.CrossRefPubMedPubMedCentral
12.
13.
14.
15.
Bissell M: Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name?. Am J Pathol . 1999, 155: 675-679.CrossRefPubMedPubMedCentral
16.
Hendrix M, Seftor E, Kirschmann D, Seftor R: Molecular biology of breast cancer metastasis: can breast cancer cells undergo vasculogenic mimicry?. Breast Cancer Res. 2000
17.
Kleer CG, van Golen KL, Merajver SD: Molecular biology of breast cancer metastasis: inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000
18.
van Golen K, Davies S, Wu Z, Wang Y, Bucana C, Root H, Chandrasekharappa S, Strawderman M, Ethier S, Merajver S: A novel putative low-affinity insulin like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999, 5: 2511-2519.PubMed
19.
Alpaugh M, Tomlinson J, Shao Z, Barsky S: A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999, 59: 5079-5084.PubMed
20.
Clare SE, Nakhlis F, Panetta JC: Molecular biology of breast cancer metastasis: the use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Res. 2000
Metadata
Title
Molecular biology of breast cancer metastasis ‘Has it spread?’: Disarming one of the most terrifying questions
Author
Patricia S Steeg
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr85

Other articles of this Issue 6/2000

Breast Cancer Research 6/2000 Go to the issue

Research article

P53 autoantibodies in 1006 patients followed up for breast cancer

Commentary

Computer-assisted mammographic imaging

Non-peer-reviewed research

The International BRCA1 /2Carrier Cohort Study: Purpose, Rationale, and Study Design

Review

Molecular biology of breast cancer metastasis Inflammatory breast cancer: clinical syndrome and molecular determinants

Review

Molecular biology of breast metastasis The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer

Review

Molecular biology of breast cancer metastasis Genetic regulation of human breast carcinoma metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits